Nanobody toolkit for human coronavirus classification

Information

  • Research Project
  • 10218812
  • ApplicationId
    10218812
  • Core Project Number
    R21AI156467
  • Full Project Number
    1R21AI156467-01A1
  • Serial Number
    156467
  • FOA Number
    PA-20-195
  • Sub Project Id
  • Project Start Date
    3/19/2021 - 3 years ago
  • Project End Date
    2/28/2023 - a year ago
  • Program Officer Name
    STEMMY, ERIK J
  • Budget Start Date
    3/19/2021 - 3 years ago
  • Budget End Date
    2/28/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    3/19/2021 - 3 years ago

Nanobody toolkit for human coronavirus classification

ABSTRACT The endemic human coronaviruses (HCoV) NL63, OC43, 229E and HKU1 have typically been associated with relatively mild and self-limiting respiratory disease resembling the common cold in healthy individuals. However, the newly emerging zoonotic coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) can cause more severe respiratory distress, especially in those with underlying health conditions and can be fatal. Coronaviruses are diverse and spillover from zoonotic reservoirs either directly to humans or via an intermediate host. Spillover is likely to be more frequent due to the ever-expanding human population and ecosystem erosion, thereby ensuring more collisions between natural and unnatural host. Our exploratory research proposal seeks to develop a small toolkit of immunoreagents that will form the basis of a logic gate to identify and classify coronaviruses. A single immunoreagent, with broad recognition of overall shared protein architecture, will allow the identification of the coronavirus genera. Separate immunoreagents with absolute specificity for unique amino-acid variation between the human and zoonotic coronaviruses will allow the further classification to a known pathogen. Such a toolkit will quickly establish if a newly emerging virus is a coronavirus we are familiar with or is a novel genus or lineage that has never before spilled over into the human population and may demand urgent follow up for epidemic or pandemic potential. Our immunoreagents are based on llama single domain antibodies or nanobodies that are inexpensive to produce at high yields in E. coli and highly modular, allowing fusion to enzymatic reporter enzymes for one-step probing of virus infected cells and facile establishment of sandwich assays. Immortalization of nanobody sequences in silico means these are immediately available to the wider research community following deposition in Genbank unlike polyclonal sera or hybridomas secreting IgG. Single-pot library technology enables a rapid response to be mounted against any newly emerged coronavirus in the future, ensuring we are more pro-active than re-active to help safeguard human health.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    150000
  • Indirect Cost Amount
    147000
  • Total Cost
    297000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:297000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    VIRB
  • Study Section Name
    Virology - B Study Section
  • Organization Name
    TEXAS BIOMEDICAL RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
    007936834
  • Organization City
    SAN ANTONIO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    782275302
  • Organization District
    UNITED STATES